SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 5 — Focused Visit (Follow-up) — Howard Hughes

PatientHoward Hughes
Date of birth1984-12-24
IdentifiersMRN HR-ML006-SYN; SSN (made up) 000-06-5571
Document date2026-07-13
AuthorAnselm Garrity-Moyo, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Ten-week review: sertraline dose, exposure therapy, his staff's part, hearing aids and pain. [S]

History of Present Illness

Mr. Hughes returns five weeks after his five-week review. The nurse called two weeks after the dose increase, and sertraline 100 mg has caused only mild sweating at night. His bronchitis from the sick visit cleared within three weeks without antibiotics. He has had nine exposure sessions in all, now twice weekly; he eats food his cook prepares without watching, and he has shaken hands twice at work. His assistant has attended two sessions, and the staff no longer wrap objects in tissue or wash before handing him things; he still asks for sealed milk bottles. Washing and checking take about two hours a day. He has used no opioid other than buprenorphine. Today, with his therapist waiting outside, he used the clinic bathroom and gave a urine sample. His hearing aids were fitted this morning. [S]

ElementDetail
RitualsAbout two hours a day; Y-BOCS 19
Sertraline100 mg for five weeks; mild night sweats
StaffTissue-wrapping and the hand-washing rule for staff stopped
Buprenorphine8 mg twice daily; no other opioid use
Hearing aidsFitted this morning

Review of Systems

SystemResultFinding
ConstitutionalNegativeMild night sweats only; weight rising
RespiratoryNegativeCough resolved
MusculoskeletalPositiveBack and chest wall pain milder
PsychiatricPositiveContamination fears less intense; no thoughts of suicide or of harming anyone

4 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Acetaminophen 300 mg with codeine 30 mg oral tablet, prescribed elsewhere since the crash as one or two tablets every 6 hours as needed, no more than 8 a day; he has been taking 10 to 12 a dayOne or two tablets every 6 hours as needed, no more than 8 a dayOral route2026-05-04 to 2026-05-11completedS
Naloxone 4 mg nasal spray, one spray into one nostril for a suspected opioid overdose, repeated every two to three minutes in the other nostril if needed; two-pack dispensed, with instruction for him and his household staffOne spray as needed for suspected overdose; repeat in 2 to 3 minutes if neededNasal route2026-05-04activeS
Buprenorphine 2 mg with naloxone 0.5 mg sublingual film for the first day: 4 mg once withdrawal is moderate (COWS 12 or more), then 2 to 4 mg every one to two hours as needed, to no more than 16 mg on the first dayFirst-day induction by the written plan, no more than 16 mgSublingual route2026-05-11 to 2026-05-12completedS
Buprenorphine 8 mg with naloxone 2 mg sublingual film, one film twice daily (16 mg a day), for opioid use disorder and pain; dispensed one week at a time at firstOne film under the tongue twice dailySublingual route2026-05-12activeS
Acetaminophen 500 mg oral tablet, two tablets three times daily (3,000 mg a day) for pain after the crash, now that codeine combination tablets have stoppedTwo tablets three times daily, no more than 3,000 mg a dayOral route2026-05-11activeS
Sertraline 50 mg oral tablet, one tablet dailyOne tablet dailyOral route2026-05-11 to 2026-06-08completedS
Sertraline 100 mg oral tablet, one tablet dailyOne tablet dailyOral route2026-06-08 to 2026-07-13completedS
Sertraline 100 mg oral tablet, two tablets daily (200 mg), the usual target range for OCDTwo tablets dailyOral route2026-07-13activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-07-13Body height191cmS
2026-07-13Body weight74.6kgS
2026-07-13Body mass index (BMI) [Ratio]20.4kg/m2S
2026-07-13Systolic blood pressure116mm[Hg]S
2026-07-13Diastolic blood pressure74mm[Hg]S
2026-07-13Heart rate74/minS
2026-07-13Respiratory rate14/minS
2026-07-13Body temperature36.7CelS
2026-07-13Oxygen saturation in Arterial blood by Pulse oximetry99%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-07-13Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]5{score}S
2026-07-13Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ]8{score}S
2026-07-13Mean score [PEG]4.7{score}S

Physical Exam

Vital signs recorded on 2026-07-13; see the Vital Signs section. [S]

SystemFinding
GeneralWell; blood pressure 116/74, pulse 74; weight 74.6 kg, BMI 20.4
EarsHearing aids in place; he follows conversation at normal volume
RespiratoryClear
PsychiatricRelaxed; shook hands on leaving; insight good

Problems

ProblemClinical statusVerificationCodeProvenance
Intrusive fears of contamination by germs for about a year, worse since the crash, with hand washing, cleaning of objects and avoidance of handshakes, shared spaces and food handled by others, taking about four hours a day; he recognizes the fears are probably excessive; cause under evaluationresolvedconfirmed R46.81S — Synthetic presenting problem anchored to his documented fear of germs; resolved into the diagnosis of OCD at the consultation. Not a claim about his real symptoms in 1947.
Obsessive-compulsive disorder, contamination type, with good or fair insight, not tic-related; Y-BOCS 28 (severe) at intake; no post-traumatic stress disorder on screeningactiveconfirmed F42.2S — Synthetic modern diagnosis made at the consultation, linked to the retrospective interpretation of his documented fears (R). Not a claim about his real diagnosis.
Opioid use disorder, moderate (four of the DSM-5-TR criteria that count for a prescribed opioid: taking more than prescribed, failed attempts to cut down, time spent getting prescriptions from two prescribers, and craving), on codeine prescribed after a crash; buprenorphine plannedactiveconfirmed F11.20S — Synthetic modern coding; tolerance and withdrawal are not counted for a medicine taken under medical supervision. Person-first language; not a claim about his real diagnosis.
Chronic pain after major trauma ten months ago (crushed chest with rib fractures, collapsed lung, other fractures and burns): chest wall, left shoulder and low back pain, PEG 6.7activeconfirmed G89.21S — Synthetic modern diagnosis anchored to his documented injuries.
Difficulty hearing conversation, worse in noise, after years of flying in loud aircraft; cause under evaluationresolvedconfirmed H91.93S — Synthetic presenting problem; resolved into a diagnosis when audiometry was done at five weeks. His documented deafness is from later years.
Bilateral high-frequency sensorineural hearing loss with a notch at 4000 Hz, consistent with noise exposure from flying; hearing aids fittedactiveconfirmed H90.3S — Synthetic modern diagnosis made at five weeks; not a claim about his real hearing in 1947.
Weight loss of about 8 kg since the crash (BMI 19.7), from eating little outside food he has prepared or inspected himself because of contamination fearsactiveconfirmed R63.4S — Synthetic nutrition problem linked to the contamination fears; not a claim about his real weight in 1947.
Acute bronchitis, likely viral, for five days; no pneumonia on examination; resolved within three weeks without antibioticsresolvedconfirmed J20.9S — Synthetic acute illness; not a historical claim.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
SurveyOCD severity (Y-BOCS, clinician-rated) and time spent on ritualsEvery visitCompleted todayY-BOCS 19; about two hours a day
ReferralExposure and response prevention: sessions attended and home practiceWeekly, then twice weeklyCompleted todayNine sessions attended, now twice weekly
Medication safetySSRI tolerability and adherence: side effects, sodium, bleeding risk, activation or new suicidal thoughtsEvery visit, and two weeks after each start or dose changeCompleted todayNurse call two weeks after the last increase done; mild night sweats only; no activation; dose raised to 200 mg today
Self-managementAccommodation by staff, reduced step by step with his consentEvery visitCompleted todayHis assistant attended two sessions; staff stopped wrapping objects and washing before handing him things
SurveyDepression (PHQ-9) and anxiety (GAD-7)At baseline and at least monthly during acute treatmentCompleted todayPHQ-9 5, item 9 scored 0; GAD-7 8
SurveySuicide risk review, safety plan and the 988 Suicide & Crisis LifelineEvery visitCompleted todayNo thoughts of suicide or of harming anyone
Self-managementOpioid use and cravings (his own account), buprenorphine adherence and side effects (sedation, constipation)Every visitCompleted todayNo cravings and no other opioid use
LaboratoryUrine drug test with fentanyl and buprenorphine, with consentAt start, then about monthly in the first monthsCompleted todayCollected today as a planned exposure: positive for buprenorphine, negative for fentanyl and other opioids
Medication safetyPrescription drug monitoring program checkBefore every controlled-substance prescriptionCompleted todayOnly this clinic's buprenorphine
Medication safetyNaloxone at home and household staff trainedEvery visitCompleted todayNaloxone at home
SurveyPain intensity and interference (PEG) and functionEvery visitCompleted todayPEG 4.7
ReferralPhysical therapy and graded activityTwice weekly, then weeklyCompleted todayMoving to weekly sessions and a home program
ExaminationWeight, meals and nutritionEvery visitCompleted today74.6 kg, up 2.6 kg since intake; three meals a day
LaboratoryKidney function, liver enzymes and albuminAt baseline and at about six months on scheduled acetaminophenUp to dateNext at about six months
ImagingHearing: audiometry, hearing aids and useAudiometry once; hearing aid review after fittingCompleted todayHearing aids fitted this morning

Goal progress:

Guideline basis: Practice Guideline for the Treatment of Patients With Obsessive-Compulsive Disorder (2007); Guideline Watch (March 2013): Practice Guideline for the Treatment of Patients With Obsessive-Compulsive Disorder (Koran LM, Simpson HB), as reported by Psychiatric News (2013); Obsessive-compulsive disorder and body dysmorphic disorder: treatment (CG31) (2005); CDC Clinical Practice Guideline for Prescribing Opioids for Pain - United States, 2022 (2022); The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update (2020); Prescription Drug Monitoring Programs (PDMPs) (2026); Hearing loss in adults: assessment and management (NG98) (2018); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026)

Follow-up: Nurse telephone call in two weeks. Preventive visit in about two months. Twenty-two-week review in about twelve weeks with laboratory tests. Call the clinic or 988 at any time. Next scheduled visit 2026-09-14: periodic adult preventive visit. [S]